[Results of the @entity4177 -89 Study in treatment of XXXX in childhood and concept of a new @entity4177 -94 protocol].

@entity1 @entity632 @entity242 @entity96 @entity5 @entity900 @entity532 @entity160 @entity1260 @entity157 @entity204 @entity4177
94 @entity1 with a primary @entity96 were registered in the Cooperative Pediatric @entity96 Study @entity4177 -89 of the GPOH from 1988 to 1992. 64 of these had a @entity4177 ( @entity4177 ), 12 a @entity157 ( @entity157 ), 2 a @entity242 and 16 a @entity5 . 51 (80%) @entity1 with an @entity4177 were 6 to 36 months of age, 9 with an @entity157 above 10 years. Initial @entity160 ( @entity160 ) was elevated in 51 @entity4177 @entity1 and exceeded the 3-fold of normal range in 45. @entity1 with low (< 100 ng/ml) and very high (> 1,000,000 ng/ml) levels had a significantly worse prognosis than those with intermediate values (p = 0.0014). @entity160 was moderately elevated in 9 @entity157 @entity1 . All other @entity5 markers were only irregularly above normal range. 48 (77%) of @entity4177 @entity1 survived, 45 (73%) are @entity5 free. All of 18 stage I and 4/5 stage II @entity1 are in remission. After chemotherapy 30/36 stage III HBs and 2/5 stage IV HBs could be resected, 9 of these @entity1 suffered from @entity5 relapse. Disease-free survival was 100% for stage I, 80% for stage II, 68% for stage III and zero for stage IV @entity4177 (p = 0.0005). @entity532 occurred after 8% of biopsies, 13% of limited primary resections and 25% of extended secondary resections. There was no perioperative @entity204 . The completeness of @entity5 resection at primary or delayed surgery correlated significantly with @entity1 disease-free survival (p < 0.0001). Chemotherapy with @entity1260 , @entity900 and @entity632 was effective in @entity4177 . 203 courses were given in 61 @entity1 .(ABSTRACT TRUNCATED AT 250 WORDS)
